Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Innoviva (NASDAQ: INVA), a diversified holding company, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. CEO Pavel Raifeld will deliver a podium presentation on Tuesday, February 11, 2025, at 2:00 p.m. Eastern Time.
The company, which maintains a core royalties portfolio and operates the Innoviva Specialty Therapeutics (IST) platform focusing on critical care and infectious diseases, will present at the virtual conference. Interested parties can access a live webcast of the presentation through the Investor Relations section of Innoviva's website. The presentation recording will remain available for replay for 90 days after the event.
Innoviva (NASDAQ: INVA), una società di holding diversificata, ha annunciato la sua partecipazione alla prossima 35ª Conferenza annuale sulle scienze della vita di Oppenheimer. Il CEO Pavel Raifeld terrà una presentazione al podio martedì 11 febbraio 2025, alle 14:00, ora orientale.
La società, che mantiene un portafoglio di royalties core e opera con la piattaforma Innoviva Specialty Therapeutics (IST) focalizzandosi sulla cura critica e sulle malattie infettive, presenterà alla conferenza virtuale. Le parti interessate possono accedere a un webcast dal vivo della presentazione attraverso la sezione Relazioni con gli investitori del sito web di Innoviva. La registrazione della presentazione rimarrà disponibile per la visione per 90 giorni dopo l'evento.
Innoviva (NASDAQ: INVA), una empresa de holdings diversificada, ha anunciado su participación en la próxima 35ª Conferencia Anual sobre Ciencias de la Salud de Oppenheimer. El CEO Pavel Raifeld ofrecerá una presentación en el podio el martes 11 de febrero de 2025, a las 2:00 p.m., hora del este.
La compañía, que mantiene una cartera de regalías central y opera la plataforma Innoviva Specialty Therapeutics (IST) enfocándose en cuidados críticos y enfermedades infecciosas, presentará en la conferencia virtual. Las partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección de Relaciones con Inversores del sitio web de Innoviva. La grabación de la presentación estará disponible para su reproducción durante 90 días después del evento.
Innoviva (NASDAQ: INVA), 다양한 포트폴리오를 보유한 회사가 다가오는 Oppenheimer 제35회 연례 헬스케어 생명과학 컨퍼런스에 참가한다고 발표했습니다. CEO Pavel Raifeld는 2025년 2월 11일 화요일 오후 2시, 동부 표준시에 기조 연설을 할 것입니다.
이 회사는 핵심 캐시 포트폴리오를 유지하며, 중환자 치료 및 감염성 질환에 중점을 두고 있는 Innoviva Specialty Therapeutics (IST) 플랫폼을 운영하고 있으며, 가상 회의에서 발표할 예정입니다. 관심 있는 분들은 Innoviva 웹사이트의 투자자 관계 섹션을 통해 발표의 라이브 웹캐스트에 접속할 수 있습니다. 발표 녹화는 이벤트 이후 90일간 재생 가능할 것입니다.
Innoviva (NASDAQ: INVA), une société de holding diversifiée, a annoncé sa participation à la prochaine 35ème Conférence annuelle sur les sciences de la santé d'Oppenheimer. Le PDG Pavel Raifeld fera une présentation au podium le mardi 11 février 2025 à 14h00, heure de l'Est.
L'entreprise, qui maintient un portefeuille de redevances central et exploite la plateforme Innoviva Specialty Therapeutics (IST) axée sur les soins critiques et les maladies infectieuses, présentera lors de la conférence virtuelle. Les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la section Relations investisseurs du site web d'Innoviva. L'enregistrement de la présentation sera disponible en replay pendant 90 jours après l'événement.
Innoviva (NASDAQ: INVA), ein diversifiziertes Holdingunternehmen, hat seine Teilnahme an der bevorstehenden 35. jährlichen Gesundheits- und Lebenswissenschaftskonferenz von Oppenheimer bekannt gegeben. CEO Pavel Raifeld wird am Dienstag, den 11. Februar 2025, um 14:00 Uhr Eastern Time eine Podiumspräsentation halten.
Das Unternehmen, das ein zentrales Lizenzportfolio verwaltet und die Plattform Innoviva Specialty Therapeutics (IST) betreibt, die sich auf die kritische Versorgung und Infektionskrankheiten konzentriert, wird auf der virtuellen Konferenz präsentieren. Interessierte Parteien können über den Bereich Investor Relations auf der Website von Innoviva auf einen Live-Webcast der Präsentation zugreifen. Die Aufzeichnung der Präsentation wird 90 Tage nach der Veranstaltung zum Abruf verfügbar sein.
- None.
- None.
A live webcast of the presentation can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website at https://investor.inva.com/presentations-events. The webcast will be available for replay for 90 days following the event.
About Innoviva
Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults.
ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250206874486/en/
Innoviva, Inc.
David Patti
Corporate Communications
(908) 421-5971
david.patti@inva.com
Investors and Media:
Argot Partners
(212) 600-1902
innoviva@argotpartners.com
Source: Innoviva, Inc.
FAQ
When is Innoviva (INVA) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors watch Innoviva's (INVA) Oppenheimer Conference presentation?
How long will Innoviva's (INVA) Oppenheimer Conference presentation be available for replay?
What are the main business segments of Innoviva (INVA) presenting at the Oppenheimer Conference?
